Recce Ltd has released a press release.
RECCE 327 Registered for Topical Burns Study in Humans
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Positive Sinusitis Patient Update - Special Access Scheme
- Positive Sinusitis Data Against Infection
- Anti-Viral Patent Granted in EU for RECCE Anti-Infectives
- S&P DJI Announces March 2021 Quarterly Rebalance
- Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange
Later from Recce Pharmaceuticals
- Positive Data on RECCE 327 Against All Six ESKAPE Pathogens
- R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO
- R327 Demonstrates World First Multiple Mechanisms of Action
- Recce Clinical Pipeline Update
- Multiple Patients Dosed in Topical Phase I/II Clinical Trial
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals